论文部分内容阅读
肺结核短程化疗是现代化疗发展的新趋向,全国肺结核短化协作组已有三批短化协作研究报告,但军内有关短化报道尚不多。为了探索适合我军特点、找出较好的化疗方案,现将我科3年多来开展肺结核短程化疗的研究结果报告如下。资料与方法一、选例标准 (一)初治浸润型肺结核的住院病人;(二)痰检抗酸杆菌阳性(集菌法);(三)年龄在14岁以上,非孕妇;(四)无心、肝、肾功能障碍,无糖尿病、矽肺等并发症。二、治疗方案 (一)所选病例分人以下3组:(1)Ⅰ组,INH+RFP+SM+PZA2个月,继以INH+RFP+EMB4个月(2SHRZ/4HRE);(2)Ⅱ组,INH+RFD+SM6个月(6RHS);(3)Ⅲ组,INH+RFD+SM
Short-course chemotherapy for tuberculosis is a new trend in the development of modern chemotherapy. Three short-term collaborative research reports have been published by the National Collaboration on Tuberculosis Shortening, but there are not many reports on shortening in the military. In order to explore the characteristics suitable for our military to find a better chemotherapy, now our department for more than 3 years to carry out tuberculosis short-term chemotherapy results reported below. Materials and Methods I. Selection Criteria (1) Inpatients with newly diagnosed infiltrative pulmonary tuberculosis; (2) Positive sputum acid-fast bacilli (collection method); (3) Non-pregnant women over 14 years of age; No heart, liver, kidney dysfunction, no diabetes, silicosis and other complications. Second, the treatment options (a) selected cases divided into the following three groups: (1) Ⅰ group, INH + RFP + SM + PZA 2 months followed by INH + RFP + EMB 4 months (2SHRZ / 4HRE) Group Ⅱ, INH + RFD + SM6 months (6RHS); (3) group Ⅲ, INH + RFD + SM